Skip to content
Screener

Treasury Stock at other companies

MiMedx Group logo
MiMedx GroupMDXG
$12.86M
CONMED logo
CONMEDCNMD
$54.68M+294%
ITG
Integer HoldingsITGR
$114.23M+325%
LeMaitre Vascular logo
LeMaitre VascularLMAT
$17.92M+10.4%
AngioDynamics logo
AngioDynamicsANGO
$7.38M0.0%

Other financials

Income statement

See full
Revenue$418.8M+0.8%
Gross profit$219.7M+5.0%
Operating income$19.3M+104%
Net income$4.5M+101%
EPS (diluted)$0.06+101%

Balance sheet

See full
Cash & equivalents$214.4M-1.6%
Total debt$2.0B+3.2%
Total equity$1.0B+0.5%
Total assets$3.6B-2.8%

Cash flow

See full
Operating cash flow$22.8M+156%
CapEx$12.3M-38.9%
Free cash flow$10.5M+193%

Valuation

See full
Market cap$1.34B+35.1%
Enterprise value$3.09B+15.4%
P/S0.8×+0.2×

Profitability

See full
Gross margin52.5%-0.1pp
Operating margin2.6%+1.3pp
Net margin-0.4%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-0.7%
Debt / equity1.9×+0.1×
Current ratio3.6×+2.4×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockCommonValue.

The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000917520-26-000058
Line itemJune 30, 2026December 31, 2025
Preferred stock; no par value; 15,000 authorized shares; none outstanding
Common stock; $0.01 par value; 240,000 authorized shares; 92,130 and 92,286 issued at June 30, 2026 and December 31, 2025, respectively921923
Additional paid-in capital1,346,2651,338,386
Treasury stock, at cost; 14,351 shares and 14,399 shares at June 30, 2026 and December 31, 2025, respectively(686,918)(689,210)
Accumulated other comprehensive loss(40,197)(30,077)
Retained earnings423,306423,441
Total stockholders’ equity1,043,3771,043,463
Total liabilities and stockholders’ equity$3,563,490$3,602,001

Item 1. Financial Statements

FAQ

What is Integra LifeSciences's treasury stock?
Integra LifeSciences (IART) reported treasury stock of $686.92M in Q2 2026.
How has Integra LifeSciences's treasury stock changed year-over-year?
Integra LifeSciences's treasury stock decreased by 0.5% year-over-year, from $690.03M to $686.92M.
What is the long-term trend for Integra LifeSciences's treasury stock?
Over 5 years (2020 to 2025), Integra LifeSciences's treasury stock has grown at a 24.0% compound annual growth rate (CAGR), from $235.1M to $689.21M.
What does treasury stock mean?
Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.

Ask your AI about Integra LifeSciences's treasury stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude